Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Geriatrics
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Geriatrics
    Hypertension, Markers of Inflammation In the Blood More Common in Offspring of Parents With AD - (DGNews)
    Addition of Ezetimibe Helps More Elderly Achieve LDL Cholesterol Goal Than Uptitration of Atorvastatin: Presented at CCC - (DGDispatch)
    African American Race Not a Factor in Decision to Undergo First-Time Colorectal Cancer Screening in Elderly Men: Presented at ACG - (DGDispatch)
    Ranibizumab Can Help Patients With Age-Related Macular Degeneration and Diabetic Macular Oedema Regain Vision: Presented at AAO-PAAO - (DGDispatch)
    Rifaximin Alleviates Symptoms Due to Small Intestine Bacterial Overgrowth: Presented at ACG - (DGDispatch)

    News archive

     Recent webcasts/CME - Geriatrics

    Webcasts/CME archive

     Recent cases - Geriatrics
      Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
      Rectal Mucosal Prolapse Syndrome as an Unusual Gastrointestinal Manifestation of Sjogren's Syndrome: A Case Report
      Liposarcoma of the Colon Presenting as an Endoluminal Mass
      A Woman with a Swollen Neck
      A 72-Year-Old Man with a Rapidly Progressive Sepsis Caused by a Rare But Life-Threatening Infection

      Cases archive
        




      my personal edition > geriatrics > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Novel Urate-Lowering Agent, Febuxostat, Shows Better Results in Older Adults With Gout Compared With Allopurinol: Presented at AGS

      By Crina Frincu-Mallos, PhD

      WASHINGTON, DC -- May 8, 2008 -- Febuxostat, a novel, nonpurine, selective inhibitor of xanthine oxidase, is effective for the treatment of gout and hyperuricemia, according to research presented here at the 2008 Annual Scientific Meeting of the American Geriatrics Society (AGS).

      "This is the first analysis of urate-lowering therapy in subjects 65 years and older suffering from gout and hyperuricemia," said lead author H. Ralph Schumacher Jr., MD, Professor, Rheumatology Division, University of Pennsylvania and VA Medical Center, Philadelphia, Pennsylvania.

      Febuxostat was tested in a phase 3, double-blind, randomised, active-controlled and placebo-controlled clinical trial of 1,832 subjects with gout and hyperuricemia, of which 295 were aged 65 years and older.

      In this older adult population, the majority were men (84%). The mean age in this subgroup was 71 years, with a mean duration of disease of 15 years.

      The study randomised patients to 1 of 3 doses of febuxostat (80, 120, and 240 mg), allopurinol 300 mg, or placebo, administered once daily in subjects with gout and normal renal function, explained Dr. Schumacher in his presentation on May 2. Patients also received 8 weeks of naproxen or colchicines for gout prophylaxis.

      The investigators sought to determine the benefit of febuxostat treatment, determined as the proportion of subjects having serum urate levels <6 mg/dL after 28 weeks of treatment.

      At baseline, the mean level of serum urate was 9.62 mg/dL, with 32% of patients having serum urate levels >10.0 mg/dL, noted Dr. Schumacher.

      Of the 79 patients treated with febuxostat 80 mg, 94% achieved serum urate levels <6.0 mg/dL. In the febuxostat 120-mg arm, 89% of 83 patients had serum urate levels <6.0 mg/dL, while all 28 subjects on febuxostat 240 mg achieved this goal.

      In the allopurinol arm, 66% of 82 patients had serum urate levels <6.0 mg/dL at the final visit, while none of the subjects in the placebo-controlled arm achieved the goal, noted Dr. Schumacher.

      A significantly greater proportion of patients with gout and hyperuricemia were successful in reducing their serum urate levels to <6.0 mg/dL compared with allopurinol (P <= .01) or placebo (P <= .01), concluded Dr. Schumacher.

      Adverse events occurred in 74% of patients treated with febuxostat and in 89% of patients treated with allopurinol, said Dr. Schumacher and colleagues. No dose-related adverse effects were observed with febuxostat.

      The most frequent adverse events were upper respiratory infections, diarrhoea, musculoskeletal and connective tissue signs and symptoms, pain, and discomfort.

      Serious adverse events, assessed by the investigators as unrelated to the study drug, occurred in 28 patients in the study; 18 of these patients continued with treatment.

      The most frequently reported serious adverse events were cardiac disorders, occurring in 4% of patients on febuxostat and 5% of patients on allopurinol, said Dr. Schumacher.

      Funding for this study was provided by TAP Pharmaceutical Products Inc.

      [Presentation title: Febuxostat (FEB) versus Allopurinol (ALLO) in the Treatment of Gout in Subjects >= 65 Years of Age. Abstract C44]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send